The presence of mutations in the CALR gene in ET patients is associated with a lower risk of thrombosis (Tefferi et al., 2014a; Rotunno et al., 2014; Pei et al., 2016; Guglielmelli et al., 2021b; Zulkeflee et al., 2021). Here, CALR is linked to essential thrombocythemia.